Goal – Profile Plasma Biomarkers of Cancer
Outcome - 45 serum samples were analyzed in five TMT®10plex sets with 6,150 peptides (mapping to 616 proteins or 310 protein groups) quantified in all samples. Analytical CV = 9.5%, with biological variability at 22% at the peptide level.
Goal – PBMC’s are the cellular component of blood and provide a rich source of circulating biomarkers. We performed unbiased, accurate quantitative proteomics to find PBMC-derived biomarkers differentiating bulbar and limb presentations of ALS.
Outcome - We have identified over 200 regulated peptides and 95 proteins in PBMC’s that show regulation between bulbar and limb endophenotypes and/or between fast and slow progressing disease. These are good candidates for further study towards an early stratification test for ALS patients to enable personalized treatment.
Collaborators - Dr. Andrea Malaspina, Queen Mary’s University, London, Professor Linda Greensmith, University College London
Goal – Identify plasma biomarkers that predict the conversion from mild cognitive impairment to Alzheimer’s disease within 12 months
Outcome – A panel of 10 plasma proteins showed changes in abundance that could predict patients with early conversion to AD with potential application in patient stratification for clinical trial enrolment.
Collaborators Institute of Psychiatry, Kings College London and University of Oxford
Goal – Identify plasma markers of developmental neurotoxic disorders
Outcome - >1700 novel biomarker candidates identifie